natco pharma semaglutide Eris Lifesciences partners with for commercialization in India | VOICE OF HEALTHCARE posted on the topic Pharma News Live | Natco

Designed to support MedTech and SaMD companies building biosensor-driven apps in areas like: GLP1 companion apps with dosing schedules, side-effect tracking, and metabolic feedback loops Personalized diabetes or weight management platforms combining CGM and biosensor insights with behavior coaching Remote monitoring and telehealth solutions for clinicians managing metabolic conditions AI-driven coaching tools that layer predictive analytics over real-time device data Traditional software development forces you to juggle device connectivity, data flows, UX, backend architecture, and strict regulations, often sequentially, slowly, and at a high cost

In Phase 3 clinical trials, participants on retatrutide lost up to 28.7% of their body weight in 68 weeks

What was driving your cravings

doi: 10.1007/s40265-015-0529-0

This necessitates sophisticated manufacturing processes and quality controls